You are here: Home >> Articles & Tutorials >>Myelodysplastic Syndrome Therapeutics – Pipeline Assessment and Market Forecasts to 2017

Myelodysplastic Syndrome Therapeutics – Pipeline Assessment and Market Forecasts to 2017

By Rajesh Gunnam : A how to tutorial about Myelodysplastic Syndrome Therapeutics, MDS, Education with step by step guide from Rajesh Gunnam.

GlobalData estimates that the global myelodysplastic syndrome (MDS) market was valued at $652.6m in 2010 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 12.2% to reach $1.5 billion by 2017. This growth forecast is primarily attributed to the currently approved drugs reaching their peak sales during the forecast period and secondarily due to a strong pipeline. The existing market is strong although with high unmet need. The market is represented by three approved drugs Vidaza (azacitidine), Dacogen (decitabine) and Revlimid (lenalidomide).

GlobalData has found that the myelodysplastic syndrome market has high unmet needs, which implies that the market is not well served by the current products in terms of efficacy and safety, and that there is high potential for new entrants. MDS therapies are largely chemotherapeutic agents that are given intravenously. Revlimid is taken as oral tablets. Thus ease of administration also adds to the unmet need present in the market. In summary, the MDS market is expected to be a relatively open market for new entrants until 2017 with many opportunities for value capture.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Myelodysplastic-Syndrome-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017

A strong pipeline with 40 molecules in various phases of clinical development, including 37 first-in-class molecules will not significantly drive the market in the forecast period. This is because the Phase III molecules that would be launched in the forecast period are primarily being studied as conditioning therapy prior to bone marrow transplant and are not likely to have much impact on the market. The Phase II first in class molecules are not likely to hit the market during the forecast period.

GlobalData, the industry analysis specialist, has released its new report, “Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global myelodysplastic syndrome (MDS) therapeutic market. The report identifies the key trends shaping and driving the global MDS therapeutic market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global MDS therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Myelodysplastic-Syndrome-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017


Visit our report store: http://www.globaldata.com


For more details contact:

pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782





Was this helpful? 1 0 Thanks,Successful Vote! 1 Comments




Related Answers & Tutorials

More answers and tutorials come with rich photos, detailed steps related to Myelodysplastic Syndrome Therapeutics – Pipeline Assessment and Market Forecasts to 2017.

You are reading Myelodysplastic Syndrome Therapeutics – Pipeline Assessment and Market Forecasts to 2017.

Featured Topic

Top Trends in Education

Top Trends

Do you like it? Share with friends!